DOSAGE INDEX / SINGLE
L-Carnitine
Research, reported schedules and supply planning.
Review L-Carnitine recovery research, the negative cancer-fatigue trial, deficiency care and limits of weight-loss and injectable-product claims.
Source: PeptideDosages.com. Independently written summaries of reported protocols, not validated treatment recommendations. Reviewed for transcription on September 21, 2026.
Research Protocol & Dosage
Source-reported examples · not treatment recommendations
- Amount
- 50–100 mg per day; a separate example reaches 200 mg
- Frequency
- Once daily
- Cycle / observation period
- 8–12 weeks; source also mentions 16 weeks
- Route / research model
- Subcutaneous
Titration & progression
A dose range is not a titration schedule. No independently verified stepwise escalation has been established for this source-reported regimen.
Supply & Planning
Compare vial strengths here. A different vial size changes the available material, not the biological dose.
Diluent & formulation
Diluent compatibility is formulation-specific. A verified manufacturer instruction is still needed before bacteriostatic water or another diluent can be listed as suitable for this research material.
Vial comparison
No single complete schedule is resolved for this entry. Enter a documented total to compare strengths; the calculator does not select a regimen.
| Vial strength | Vials needed |
|---|---|
| 200 mg | Enter a total |
Enter a positive material total.
Material minimum only: round total material ÷ vial content up to a whole vial. Actual supply may be higher because of single-use packaging, discard dates, dead space or losses. No validated multi-use storage period is assumed.
Reported Research Results
Selected observations from the cited research. Each finding retains its study population, formulation and limitations.
- A randomized, double-blind, placebo-controlled study recruited 80 adults and had 73 completers. Participants undertook a maintenance exercise program followed by a high-volume challenge. L-Carnitine tartrate was associated with better perceived recovery and soreness, lower creatine kinase and smaller declines in strength and power than placebo after the challenge. [1]
- A phase 3 trial randomized 376 people with cancer-related fatigue to oral L-Carnitine or placebo. After four weeks, carnitine levels increased, but fatigue did not improve more than with placebo; the between-group comparison was nonsignificant. Secondary fatigue, depression and pain outcomes also did not show a benefit, and the reported deficient subgroup did not resolve the negative result. [2]
- An earlier uncontrolled study of selected chemotherapy patients with low carnitine had reported improved fatigue after supplementation and called for a randomized trial. Its design could not distinguish treatment effects from other explanations as well as the later placebo-controlled investigation. [3]
- NIH lists gastrointestinal symptoms and a fishy body odor among possible effects of higher supplemental intakes, with particular concerns for people with uremia or seizure disorders. It also discusses TMAO-related cardiovascular questions while noting that their implications require further research. [4]
Sourcing & Vendor Information
No compound-specific affiliate destination is listed here yet. Browse the Vendors Index for the available supplier records and disclosed relationships.
Sources & Further Reading
Medical publications and supporting literature from the corresponding protocol bibliographies, combined across vial strengths. Supplier and commercial catalog references are excluded. Duplicate destinations appear once. Inclusion does not mean that a paper validates the reported dose, or that an ingredient study tests the finished blend.
Bibliography checked September 22, 2026: 13 entries mapped from 1 source page. Medical and supporting references are retained below; supplier entries are excluded.
- 2021 original recovery study
- 2012 randomized trial
- 2002 pilot study
- NIH safety section
- Journal of the International Society of Sports Nutrition (2020)Further reading · Listed in reference bibliography.
- Clinical Nutrition ESPEN (2020)Further reading · Listed in reference bibliography.
- Clinical Pharmacokinetics (2003)Further reading · Listed in reference bibliography.
- Molecular Nutrition & Food Research (2018)Further reading · Listed in reference bibliography.
- American Journal of Kidney Diseases (2001)Further reading · Listed in reference bibliography.
- Advances in Therapy (2019)Further reading · Listed in reference bibliography.
- Drugs.com (2024)Further reading · Listed in reference bibliography.
- CDC Vaccine Administration GuidelinesGeneral guidance · Listed in reference bibliography.
- NCBI BookshelfFurther reading · Listed in reference bibliography.
- CDC Pink Book (14th Edition)General guidance · Listed in reference bibliography.
- Linus Pauling Institute, Oregon State University (2022)Further reading · Listed in reference bibliography.
Reported schedule reference: PeptideDosages.com. Research findings are summarized independently from the listed sources.